The compliance audit we ran on 40 supplement listings, what gets suppressed, what slips through

We pulled 40 supplement listings at random from our client base in March 2026 and ran them through the same compliance audit Amazon’s automated review runs. 23 of the 40 had at least one violation severe enough to trigger suppression. 11 had violations severe enough to trigger an account-level Notice of Concern if surfaced. Only 6 of the 40 cleared the audit cleanly.

This is the full teardown. Every category of violation, the suppression rate it carries, the listings that slipped through despite carrying obvious risk, and the operator-level pattern that explains why the same brands keep getting hit.

The five violation categories and what each costs

Category 1: Disease claims dressed as structure-function claims. 19 of 40 listings carried this violation. Examples: “supports healthy blood sugar response” written immediately above an image showing a glucose meter at 95 mg/dL; “promotes joint comfort” with a bullet that read “ideal for arthritis sufferers.” The structure-function claim is legal in isolation. The visual or contextual companion turns it into a disease claim. Suppression rate when both elements are present: 81% within 90 days. Suppression rate when only the structure-function language is present: 12%.

Category 2: “Clinically proven” without an SKU-specific study. 14 of 40 used some variant of “clinically proven,” “clinically tested,” or “clinically studied.” Of those 14, only 3 had a study on the actual finished formulation. The other 11 were citing an ingredient study from a supplier. Amazon’s 2026 model now requires the study to be on the finished SKU at the labeled dose. The 11 listings citing ingredient studies are running with a 67% probability of suppression in the next two quarters.

Category 3: Missing or buried FDA disclaimer. 9 of 40 listings either omitted the “These statements have not been evaluated by the FDA” disclaimer or buried it in image text small enough to fail OCR. The disclaimer requirement looks ceremonial. Amazon’s automated review treats it as a binary: missing equals suppression in 94% of cases within 60 days.

Category 4: Cross-surface inconsistency. 22 of 40 had at least one claim that appeared on the brand store or A+ image text but did NOT appear in the listing bullets, and vice versa. The 2026 review model treats inconsistency as a flag because it implies one of the surfaces was edited to clean up a violation while the other was missed. Suppression rate when 3+ inconsistencies are present: 58%. When 1-2 are present: 19%.

Category 5: Ingredient-free claims without COA backing. 7 of 40 carried “free from” claims (gluten-free, dairy-free, soy-free) where the supplied Certificate of Analysis did not specifically test for the absence of that allergen. Amazon’s review now requests the COA on a sampling basis. Suppression rate when the COA is requested and missing: 100%.

What slipped through the audit

Some of the most striking findings were the violations that did not trigger suppression. Three patterns held.

Pattern A: aggressive claims on listings with very low session volume. Two listings in the cohort carried borderline disease claims and had been live for 14+ months without suppression. Both were sub-300-session-per-month ASINs. Amazon’s automated review samples by traffic. Low-traffic listings are not “compliant”, they are unaudited. The day they win a placement and traffic spikes, the audit catches up within 14 to 21 days.

Pattern B: claims wrapped in customer-quote framing. “Customers tell us they feel calmer” technically attributes the claim to a third party. Amazon’s 2026 model has tightened on this but still under-enforces relative to the underlying risk. We saw 4 listings using customer-quote claim framing that should have been pulled and were not. We do not recommend running this as a strategy. The framing is on Amazon’s roadmap and the brands relying on it are running with a stop-loss they did not set themselves.

Pattern C: violations only in the supplement-facts image. OCR coverage on supplement-facts panels is still uneven. Listings that put aggressive claim language inside the supplement-facts panel image got read inconsistently. This is going to close in H2, Amazon has been hiring OCR engineers specifically against this gap, but in March 2026 it was a real gap.

The full FDA enforcement context for these patterns is in FDA-restricted claim language on Amazon, the 2026 enforcement pattern.

The operator pattern behind repeat offenders

Six of the 40 listings had been suppressed at least once before our audit and had been re-listed. Five of those six failed the audit again. The pattern was identical: the brand fixed the specific claim that triggered the suppression and left every other violation in place. Amazon’s 2026 model does not work that way, once a SKU has a suppression record, the next review pass audits the entire listing, not just the previous violation.

The six clean listings were operationally distinct from the rest of the cohort. All six had a per-SKU compliance binder updated within the last 12 months, all six had cross-surface consistency checks in their listing-update SOP, and all six were managed by an operator whose comp included a compliance KPI. The boring stuff is the stuff that wins.

If you want this audit run on your top 20 supplement listings with the per-SKU action list and the documentation chain rebuild, Get a free audit. We will hand back the audit, the violation map, and the rebuild order. The rebuild itself is yours.